Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQSTNASDAQ:AUPHNASDAQ:BGMNASDAQ:ETNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$2.92+2.8%$2.77$2.20▼$5.80$288.70M2.591.48 million shs1.00 million shsAUPHAurinia Pharmaceuticals$8.24+1.5%$8.02$4.99▼$10.67$1.13B1.21.35 million shs1.07 million shsBGMQilian International Holding Group$11.12-2.0%$10.48$5.26▼$14.78$1.08B1.3227,998 shs14,580 shsETNB89bio$8.02+6.2%$7.43$4.16▼$11.84$1.17B1.251.33 million shs2.01 million shs20 Stocks to Sell NowGet This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+2.82%+3.55%+0.69%-5.19%-13.10%AUPHAurinia Pharmaceuticals+1.48%+1.85%+2.49%+3.00%+61.89%BGMQilian International Holding Group-0.10%+1.65%-2.80%+13.35%+1,111,999,900.00%ETNB89bio+6.23%+21.15%+10.32%-16.80%-5.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAQSTAquestive Therapeutics1.5172 of 5 stars3.62.00.00.02.20.00.0AUPHAurinia Pharmaceuticals2.6286 of 5 stars3.52.00.00.02.10.81.9BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/AETNB89bio2.9963 of 5 stars4.41.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.14Buy$10.67265.30% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5039.56% UpsideBGMQilian International Holding Group 0.00N/AN/AN/AETNB89bio 2.89Moderate Buy$27.25239.78% UpsideCurrent Analyst Ratings BreakdownLatest AQST, BGM, AUPH, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/2/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/22/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/14/2025ETNB89bioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$11.003/13/2025ETNB89bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/10/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/7/2025AQSTAquestive TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$7.003/7/2025AQSTAquestive TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/7/2025AQSTAquestive TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.003/7/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M5.02N/AN/A($1.59) per share-1.84AUPHAurinia Pharmaceuticals$235.13M4.79N/AN/A$2.63 per share3.13BGMQilian International Holding Group$25.10M43.08N/AN/A$6.10 per share1.82ETNB89bioN/AN/AN/AN/A$5.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$7.87M-$0.52N/AN/AN/A-59.75%N/A-33.96%5/6/2025 (Estimated)AUPHAurinia Pharmaceuticals-$78.02M$0.05N/A14.71N/A-10.23%-4.41%-3.07%5/1/2025 (Estimated)BGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AETNB89bio-$142.19M-$3.43N/AN/AN/AN/A-59.58%-52.21%5/8/2025 (Estimated)Latest AQST, BGM, AUPH, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ETNB89bio-$0.50N/AN/AN/AN/AN/A5/6/2025Q1 2025AQSTAquestive Therapeutics-$0.17N/AN/AN/A$12.23 millionN/A5/1/2025Q1 2025AUPHAurinia Pharmaceuticals$0.09N/AN/AN/A$61.06 millionN/A3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/A3/5/2025Q4 2024AQSTAquestive Therapeutics-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A6.375.91AUPHAurinia Pharmaceuticals0.175.605.11BGMQilian International Holding GroupN/A3.392.82ETNB89bio0.0911.6611.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%AUPHAurinia Pharmaceuticals36.83%BGMQilian International Holding GroupN/AETNB89bioN/AInsider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics7.85%AUPHAurinia Pharmaceuticals4.30%BGMQilian International Holding Group58.66%ETNB89bio2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16098.87 million84.02 millionOptionableAUPHAurinia Pharmaceuticals300136.65 million137.02 millionOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/AETNB89bio40145.98 million103.15 millionOptionableAQST, BGM, AUPH, and ETNB HeadlinesRecent News About These Companies89bio (NASDAQ:ETNB) Stock Price Up 4.5% - Time to Buy?April 30 at 4:55 PM | marketbeat.comRaymond James Financial Inc. Acquires Shares of 377,370 89bio, Inc. (NASDAQ:ETNB)April 30 at 3:48 AM | marketbeat.comBarclays PLC Buys 425,206 Shares of 89bio, Inc. (NASDAQ:ETNB)April 29 at 3:49 AM | marketbeat.com89bio's (ETNB) "Sell (D-)" Rating Reiterated at Weiss RatingsApril 27, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Shares Purchased by JPMorgan Chase & Co.April 26, 2025 | marketbeat.comInvestors Buy Large Volume of 89bio Put Options (NASDAQ:ETNB)April 24, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Trading Up 6.1% - Time to Buy?April 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Makes New Investment in 89bio, Inc. (NASDAQ:ETNB)April 23, 2025 | marketbeat.comRock Springs Capital Management LP Makes New Investment in 89bio, Inc. (NASDAQ:ETNB)April 23, 2025 | marketbeat.com89bio Target of Unusually Large Options Trading (NASDAQ:ETNB)April 23, 2025 | americanbankingnews.comGeode Capital Management LLC Grows Position in 89bio, Inc. (NASDAQ:ETNB)April 21, 2025 | marketbeat.comShort Interest in 89bio, Inc. (NASDAQ:ETNB) Grows By 38.3%April 20, 2025 | marketbeat.comQuoc Le-Nguyen Sells 15,329 Shares of 89bio, Inc. (NASDAQ:ETNB) StockApril 18, 2025 | insidertrades.com89bio: A Buy With Strong Market Opportunity In MASH And SHTGApril 18, 2025 | seekingalpha.com89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage DevelopmentApril 17, 2025 | seekingalpha.comUniversity of Wisconsin Foundation Purchases 193,225 Shares of 89bio, Inc. (NASDAQ:ETNB)April 15, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Shares Purchased by Alliancebernstein L.P.April 14, 2025 | marketbeat.comVanguard Group Inc. Grows Stock Holdings in 89bio, Inc. (NASDAQ:ETNB)April 14, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Given Average Recommendation of "Moderate Buy" by AnalystsApril 13, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Sets New 1-Year Low - Time to Sell?April 12, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Receives Sell (D-) Rating from Weiss RatingsApril 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAQST, BGM, AUPH, and ETNB Company DescriptionsAquestive Therapeutics NASDAQ:AQST$2.92 +0.08 (+2.82%) As of 04/30/2025 04:00 PM EasternAquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Aurinia Pharmaceuticals NASDAQ:AUPH$8.24 +0.12 (+1.48%) As of 04/30/2025 04:00 PM EasternAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Qilian International Holding Group NASDAQ:BGM$11.12 -0.23 (-2.03%) As of 04/30/2025 04:00 PM EasternQilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.89bio NASDAQ:ETNB$8.02 +0.47 (+6.23%) As of 04/30/2025 04:00 PM Eastern89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
